Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $3.31, $0.16 worse than the analyst estimate of $3.47. Revenue for the quarter came in at $730.3 million versus the consensus estimate of $747.26 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.